Data from the FLAURA2 trial suggest AstraZeneca could soon be able to expand use of Tagrisso in the first-line setting, widening the gap over Johnson & Johnson’s Rybrevant.
AstraZeneca PLC's aim of securing the market-leading position of its biggest seller Tagrisso has received a major boost with the release of late-stage data demonstrating the additional benefit of combining the drug with chemotherapy for lung cancer patients.
The UK major has announced positive high-level results from the FLAURA2 Phase III trial which showed that Tagrisso (osimertinib) in...
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
